Essra Ridha
Corporate Officer/Principal en The Royal College of Physicians .
Fortuna: 23 504 $ al 31/05/2024
Cargos activos de Essra Ridha
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| The Royal College of Physicians | Corporate Officer/Principal | - | - |
Historial de carrera de Essra Ridha
Antiguos cargos conocidos de Essra Ridha.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| TECTONIC THERAPEUTIC, INC. | Director Técnico/Científico/I+D | 01/10/2021 | 20/06/2024 |
| TECTONIC THERAPEUTIC, INC. | Director Técnico/Científico/I+D | 01/04/2021 | 01/07/2021 |
| SANGAMO THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/06/2019 | 01/02/2021 |
Formación de Essra Ridha.
| Royal Free Hospital Medical School | Doctorate Degree |
| UCL Medical School | Doctorate Degree |
| University College London | Undergraduate Degree |
Estadísticas
Internacional
| Reino Unido | 5 |
| Estados Unidos | 3 |
Operativa
| Chief Tech/Sci/R&D Officer | 3 |
| Doctorate Degree | 2 |
| Corporate Officer/Principal | 1 |
Sectorial
| Consumer Services | 5 |
| Health Technology | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Avrobio, Inc.
 Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Essra Ridha
- Experiencia
